Functional Decline Precedes Cardiovascular Disease Events By Many Years
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

For listenersOffer from Amazon

Turn quiet afternoons into listening time

  • Thousands of audiobooks, podcasts and originals
  • Listen on your phone, tablet or Echo — also offline
  • Cancel anytime
Try Audible free Free trial for new members
As an affiliate, we earn on qualifying purchases.

A study of 12,015 older adults found that people who later had cardiovascular events already had worse functional-aging measures than matched controls, with gaps widening in the five years before an event. The findings show an association over time; they do not establish that functional decline causes cardiovascular disease or that screening based on these measures prevents events.

A study published online Sept. 23 in JAMA Cardiology found that people who later experienced cardiovascular disease events had worse measures of frailty, intrinsic capacity and physical health-related quality of life than matched participants, with differences evident up to a decade before an event. The analysis followed data from 12,015 participants in the Aspirin in Reducing Events in the Elderly cohort, offering evidence that functional decline may precede clinically apparent cardiovascular disease by years.

Researchers examined 2,403 participants who experienced a cardiovascular event and 9,612 matched controls. They compared functional performance trajectories over time, including measures of frailty, intrinsic capacity and physical health-related quality of life. The event group had worse profiles than controls during the years preceding diagnosis, according to the report.

The differences widened markedly in the five years before an event. Over time, the event group showed greater increases in frailty and sharper declines in intrinsic capacity and physical quality of life. The study reported changes in the Frailty Index (β = 0.78), Fried phenotype frailty (β = 0.05), intrinsic capacity (β = −0.34) and physical health-related quality of life (β = −0.55). These are study estimates; the report does not provide enough detail to interpret them as individual-level predictions.

Similar patterns appeared across components of the cardiovascular composite outcome, but the timing varied. Differences emerged at least 10 years before heart failure and fatal coronary heart disease, while the report says divergence for myocardial infarction and stroke occurred later. The supplied account does not specify the exact timing for those latter outcomes.

At a glance
reportWhen: Published online Sept. 23, 2026; report…
The developmentA JAMA Cardiology study reports that functional-aging measures were worse for people who later experienced cardiovascular events, with differences visible years beforehand.

A Longer Window for Clinical Review

The findings suggest that changes in everyday physical function and broader measures of aging may become apparent before a cardiovascular event is diagnosed. If future work confirms the pattern and identifies measures that are useful in practice, clinicians could have more time to review a patient’s overall health and cardiovascular risk rather than waiting for an acute event to reveal underlying problems.

That possibility is not the same as evidence that monitoring frailty or quality-of-life scores will prevent heart attacks, strokes or heart failure. The study examined trajectories associated with later events; it did not test a screening program or early intervention. For readers, the main implication is a potential link between long-term functional change and cardiovascular health—not a new individual risk test or a diagnosis based on decline alone.

Products Worth Considering

As an affiliate, we earn on qualifying purchases.

How Researchers Tracked Functional Change

The report describes a nested case-control study using participants from the Aspirin in Reducing Events in the Elderly cohort. Researchers compared people who went on to have cardiovascular events with matched controls and assessed differences in functional-aging measures before those events. The analysis was published as “Multidimensional Aging Trajectories Preceding Cardiovascular Events” in JAMA Cardiology, with Aung Zaw Zaw Phyo of Monash University in Melbourne and colleagues as authors.

The study focused on more than a single physical measure. Frailty reflects vulnerability across health domains, while intrinsic capacity refers to a person’s abilities across areas of functioning. Physical health-related quality of life captures participants’ reported view of their physical health. The report says the event group had worse profiles across these measures, but the supplied material does not detail the assessment schedules, participants’ ages, or how each measure was collected.

“Declines in functional aging markers were prominent before clinically apparent CVD.”

— Aung Zaw Zaw Phyo and colleagues, study authors

Limits of the Evidence

The findings establish an association in this analysis, not that functional decline causes cardiovascular disease. The supplied report also does not provide enough information to determine how well these measures predict an event for an individual, whether results apply to populations outside this cohort, or how other health conditions might affect the trajectories.

No intervention was tested, so it remains unclear whether acting on early changes in frailty, intrinsic capacity or physical quality of life would prevent or delay cardiovascular events. The reported study details do not include absolute event risks, the length and schedule of follow-up assessments, or the clinical thresholds that might prompt further evaluation. Those questions matter before the findings can be translated into routine screening recommendations.

From Trajectories to Clinical Use

The immediate next step is for researchers and clinicians to assess whether these patterns can be replicated and whether the measures add useful information to established cardiovascular risk assessments. Further studies would need to clarify how accurately functional changes identify people at higher risk and whether follow-up evaluation or intervention based on those changes improves outcomes.

Until that evidence is available, the study supports attention to the relationship between functional health and later cardiovascular events, but it does not set out a new screening protocol. The paper’s publication in JAMA Cardiology provides a basis for further research; the report gives no specific timetable for additional studies or clinical guidance.

Key Questions

What did the study find?

Participants who later experienced cardiovascular events had worse frailty, intrinsic-capacity and physical quality-of-life profiles than matched controls, with differences visible years before the event and widening in the final five years.

How many people were included?

The analysis included 12,015 participants: 2,403 people who experienced a cardiovascular event and 9,612 matched controls from the Aspirin in Reducing Events in the Elderly cohort.

Does the study show that functional decline causes heart disease?

No. The study reports that functional decline measures were associated with later cardiovascular events. It does not establish cause and effect or show that preventing functional decline would prevent an event.

Does this mean people should use frailty scores to predict their own risk?

The report does not establish these measures as an individual prediction test or recommend a screening protocol. It also does not show that a particular score should prompt treatment. Decisions about cardiovascular risk and health changes should be discussed with a qualified health professional.

Which events showed the earliest differences?

The report says differences appeared at least 10 years before heart failure and fatal coronary heart disease. For myocardial infarction and stroke, divergence occurred later, but the supplied account does not give exact time points.

Source: rss

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

What Is Posterior Cortical Atrophy? One Couple’s Road To Diagnosis

Scott Cunningham’s PCA diagnosis followed years of visual and spatial difficulties that were initially mistaken for eye problems.

Neurocrine Biosciences Surges In Global Coverage

Neurocrine Biosciences sees a significant increase in worldwide media mentions, indicating rising interest in its developments and potential breakthroughs.

Is the Innovo Deluxe iP900AP Fingertip Pulse Oximeter Worth It? Honest Take + Alternatives

A detailed look at the Innovo iP900AP pulse oximeter — accurate readings, useful features, but some limitations. Is it worth it for your needs?